Corley Jesse Anderson Buys 37,037 Shares of RxSight, Inc.

On June 17, 2026, Corley Jesse Anderson purchased 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). The shares were acquired without a pre-planned trading arrangement, adding to the insider activity at the medical device company. Shares of RxSight traded around $4.73 at the time.

Other Institutional Activity in RxSight, Inc.

Institutional investors have been active in RxSight, Inc. recently. BlackRock, Inc. increased its holdings by 482,086 shares, bringing its total to about 3,187,092 shares valued at approximately $19.63 million. Meanwhile, Millennium Management LLC reduced its position by 69,579 shares, leaving it with 2,059,459 shares valued at $12.69 million. Artisan Partners Limited Partnership also cut its stake by 98,580 shares, holding 2,058,684 shares worth about $12.68 million. Nomura Holdings Inc. maintained its position with 2,000,060 shares valued at $12.32 million, while No Street GP LP added 25,000 shares, ending with 2,000,000 shares valued at $12.32 million.

RxSight, Inc. Stock Snapshot

Shares of RxSight, Inc. (NasdaqGM: RXST) are trading near $4.73. The company has a market capitalization of approximately $195.8 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a 52-week low of $4.48 and a high of $14.29, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. RxSight has a current ratio of 10.2 and a quick ratio of 8.779, indicating strong liquidity, but a debt-to-equity ratio of 4.05.

Recent Earnings

RxSight, Inc. reported revenue of $127.5 million, though it saw a revenue decline of 18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%. The next earnings report is scheduled for August 6, 2026.

Insider Buying and Selling at RxSight, Inc.

On June 17, 2026, several insiders, including Tammenoms Bakker Juliet, Warner Robert Keith, Palmisano Robert, Link William PhD, Maniar Shweta, and Corley Jesse Anderson, each bought 37,037 shares. These purchases were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On May 7, 2026, Wells Fargo maintained a 'hold' rating with a $9.00 price target for RxSight, Inc. Needham maintained a 'buy' rating with an $11.00 target on the same date. Overall, the consensus among analysts is neutral with an average target price of $8.79.

About RxSight, Inc.

RxSight, Inc. is a healthcare company based in Aliso Viejo, California, specializing in medical devices. It focuses on developing and selling light adjustable intraocular lenses used in cataract surgery. The company's flagship product, the RxSight system, allows doctors to adjust and enhance patients' vision post-surgery. The system includes a light adjustable lens and a light delivery device. Dr. Ronald M. Kurtz serves as the CEO, and the company employs 461 people.

Bottom Line

Corley Jesse Anderson's recent purchase of RxSight, Inc. shares adds to the insider activity at the company. Investors keep an eye on such transactions for insights into potential company performance. It's important to remember that insider transactions are reported after the fact and don't necessarily indicate future stock performance.